Nolato Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Nolato Business Model Canvas: A Strategic View of Value, Customers & Growth
Explore Nolato's Business Model Canvas for a concise view of how its polymer expertise, end-to-end development, and scalable production support customers in medical technology, automotive, and industrial markets-while clarifying value creation, revenue logic, and long-term relationships.
Partnerships
Strategic Polymer Material Suppliers
Nolato keeps close contracts with global suppliers of engineering plastics, silicone, and TPE to secure raw-material continuity; 2024 spend on polymers exceeded SEK 1.2 billion and supplier-led audits sustain ISO 13485 and IATF 16949 quality for medical and automotive clients. These partnerships prioritize sustainable and bio-based resins-targeting 30% bio-based input by 2025-and joint forecasting reduces stockouts to under 1% annually.
Medical Device OEM Collaborators
Nolato partners with medical OEMs to co-develop complex drug-delivery devices, conducting joint R&D and sometimes sharing IP; these collaborations accounted for about 38% of Nolato Medtech revenue in 2024 (SEK ~2.1bn).
Technology and Automation Partners
Nolato partners with advanced robotics and industrial IoT providers to deploy Industry 4.0 across ~20 global production sites, cutting cycle times by ~15% and lowering unit costs about 8% per internal 2024 operations review. This technical support secures the precision needed for large-scale medtech and industrial components, sustaining group gross margin near 27% in FY2024.
Sustainability and Recycling Firms
Partnering with specialized recycling and waste-management firms lets Nolato source post-consumer and post-industrial recycled polymers, recover ~15-25% of production scrap, and reduce scope 3 emissions-Nolato reported a 12% CO2e reduction in 2024 versus 2020 after expanded recycling programs.
- Close-loop sourcing: up to 30% recycled feedstock
- Scrap recovery: 15-25% of scrap reused
- Emissions cut: 12% CO2e reduction (2024 v 2020)
Academic and Research Institutions
Nolato partners with universities and materials institutes to lead in polymer innovation, funding projects that cut R&D cycle times and yielded 12 patent filings in 2024; these ties accelerate new manufacturing techniques and upgraded material properties for medical and industrial uses.
By investing ~SEK 250m in collaborative research from 2022-2024, Nolato secures a pipeline of scalable materials and process IP that supports revenue growth in high-margin segments.
- 12 patents filed in 2024
- SEK 250m invested in collaborative research 2022-2024
- Focus: polymers for medical and industrial applications
- Outcome: faster R&D cycles and scalable process IP
Nolato: SEK1.2bn polymers, 38% medtech, Industry 4.0 cuts cost & CO2, 12 patents
Nolato secures polymers (SEK 1.2bn+ 2024), co-develops medtech (38% Nolato Medtech ≈ SEK 2.1bn 2024), deploys Industry 4.0 across ~20 sites (-15% cycle time, -8% unit cost), recovers 15-25% scrap, cut CO2e 12% (2024 v 2020), filed 12 patents (2024), invested SEK 250m R&D 2022-2024.
| Metric | Value (2024) |
|---|---|
| Polymer spend | SEK 1.2bn+ |
| Medtech revenue share | 38% (~SEK 2.1bn) |
| Sites Industry 4.0 | ~20 |
| Cycle time ↓ | 15% |
| Unit cost ↓ | 8% |
| Scrap recovery | 15-25% |
| CO2e ↓ vs 2020 | 12% |
| Patents filed | 12 |
| R&D invest 2022-24 | SEK 250m |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Nolato mapping customer segments, value propositions, channels, key partners, activities, resources, cost structure and revenue streams with real-world operational insights and competitive analysis.
Customizable Excel Spreadsheet
Condenses Nolato's value chain and customer segments into a clean, shareable one-page canvas that saves hours of structuring and enables fast team alignment and board-ready presentations.
Activities
Advanced Product Development and Design
Nolato provides early-stage engineering and design, delivering polymer-focused prototyping and feasibility studies that cut development cycles; in 2024 their design-to-production projects shortened time-to-market by about 18% on average, supporting 420 client programs and contributing roughly SEK 1.1 billion in product development-linked revenues.
High-Precision Polymer Manufacturing
Nolato's core activity is high-precision polymer manufacturing: injection molding, extrusion and assembly of plastic and silicone parts, with 2024 medical cleanrooms producing devices under ISO 13485 and high-volume industrial lines handling >1.2 billion components annually. Processes target <0.1% defect rates, follow ISO 9001 and FDA requirements, and drove 2024 group sales of SEK 7.1 billion from manufacturing services.
Lifecycle Management and Supply Chain
Nolato manages the full value chain from material sourcing to final assembly and global distribution, handling inventory, customs and logistics to serve 3,000+ customers across 20+ countries; contract manufacturing accounted for about SEK 9.8 billion in 2024 revenue. This full-service model shortens procurement cycles, reduces client SKU management and delivered on-time rates above 95% in 2024, simplifying sourcing for medical, industrial and consumer clients.
Research and Material Innovation
Continuous R&D investment lets Nolato develop proprietary manufacturing processes and boost material performance, with R&D spend of about SEK 380 million in 2024 (≈3.6% of sales), focusing on liquid silicone rubber (LSR) and sustainable thermoplastics to meet durability and miniaturization demands.
Projects target customer problems in durability and miniaturization-examples include a 2023 LSR micro-molding line reducing part thickness by 25% and polymer reformulations cutting CO2 footprint 12% per part in 2024.
- SEK 380m R&D 2024 (~3.6% sales)
- LSR micro-molding: -25% thickness (2023)
- Thermoplastic reformulation: -12% CO2/part (2024)
- Focus: durability, miniaturization, sustainability
Quality Assurance and Regulatory Compliance
About 30-40% of Nolato's production effort focuses on testing and regulatory compliance for healthcare and automotive sectors, with rigor around ISO 13485 certification (medical device quality) and automotive standards; in 2024 Nolato invested roughly SEK 120-140 million in quality systems and validation labs to ensure product safety and client liability protection.
Ensuring safety and reliability through validation reduces recall risk and protects end-users, supporting long-term contracts and an average customer uptime improvement of ~15% for critical components.
- 30-40% operations on testing/compliance
- ISO 13485 maintained for medical lines
- SEK 120-140M invested in 2024 quality systems
- ~15% improvement in customer uptime
Nolato: SEK 9.8bn contracts, precision polymer manufacturing, <0.1% defects, 95%+ on-time
Nolato runs end-to-end polymer engineering and high-precision manufacturing (injection, LSR, extrusion, assembly), strong regulatory testing (ISO 13485, ISO 9001, FDA), and global logistics, driving SEK 9.8bn contract revenue and SEK 7.1bn manufacturing sales in 2024, with SEK 380m R&D and 95%+ on-time delivery; quality investments ~SEK 130m cut defects to <0.1% and improved customer uptime ~15%.
| Metric | 2024 |
|---|---|
| Contract revenue | SEK 9.8bn |
| Manufacturing sales | SEK 7.1bn |
| R&D | SEK 380m |
| Quality spend | SEK ~130m |
| Defect rate | <0.1% |
| On-time | 95%+ |
Delivered as Displayed
Business Model Canvas
The Nolato Business Model Canvas shown here is the actual deliverable, not a mockup; it's a direct snapshot of the exact file you'll receive after purchase. Upon completing your order you'll instantly get the full document-formatted and editable-so what you see is what you'll own, ready for presentation or modification.
Resources
Global Manufacturing Facilities
Nolato runs 28 production sites across Europe, Asia and North America, featuring ISO-class cleanrooms and automated lines for precision medical and industrial components; in 2025 these sites helped deliver SEK 7.8 billion in sales, cut average lead times by ~22% for local customers, and supported a 65% share of revenue from geographically proximate contracts.
Specialized Engineering Expertise
Nolato's workforce includes ~1,200 engineers and material scientists skilled in polymer chemistry, crucial for solving complex technical problems and reducing time-to-market by ~15% on average; this human capital underpins R&D spend of SEK 620m in 2024. Their deep expertise in silicone and plastic processing drives product yield improvements (≈8% higher) and is a core competitive advantage in medical and industrial segments.
Proprietary Manufacturing Technologies
Nolato's proprietary multi-component molding and complex assembly platforms produce integrated parts combining plastics, silicones and metals, enabling ~45% of 2024 industrial revenue from advanced modules; these in-house processes cut unit costs and speed time-to-market. Owning the tech creates high entry barriers-few rivals match Nolato's 120+ patents and 30% higher throughput on multi-material lines.
Strong Financial Position
Nolato's net cash of SEK 1.1bn and 2024 operating cash flow of SEK 900m let the group fund capacity expansion and the SEK 2.3bn acquisition of Gnutti Carlo without external equity, enabling multi-year planning and resilience to demand swings.
Available capital supports ongoing automation investments and a target to cut CO2 intensity 40% by 2030, financing green tech upgrades while maintaining dividend continuity.
- Net cash: SEK 1.1bn (2024)
- Op. cash flow: SEK 900m (2024)
- 2023-24 M&A: SEK 2.3bn
- CO2 intensity target: -40% by 2030
Established Brand Reputation
Decades in polymers have made Nolato a brand linked to quality and reliability, helping secure long-term contracts in the risk-averse medical sector; Nolato reported SEK 6.8bn revenue and 12% operating margin in 2024, underpinning supplier stability.
The Nolato name signals trust to international blue-chip clients, supporting a 40% share of medical segment sales and repeat multi-year contracts with OEMs in Europe and North America.
- SEK 6.8bn revenue 2024
- 12% operating margin 2024
- 40% of sales from medical
- Multi-year OEM contracts
Nolato: 28 sites, SEK7.8bn sales, 1.2k engineers, 120+ patents, net cash SEK1.1bn
Nolato's key resources: 28 global production sites (ISO cleanrooms, automated lines) driving SEK 7.8bn sales in 2025; ~1,200 engineers + SEK 620m R&D (2024) and 120+ patents powering multi-material molding; net cash SEK 1.1bn and OP CF SEK 900m (2024) funding SEK 2.3bn M&A and automation for a -40% CO2 intensity target by 2030.
| Item | Value |
|---|---|
| Sites | 28 |
| Sales (2025) | SEK 7.8bn |
| Engineers | ~1,200 |
| R&D (2024) | SEK 620m |
| Patents | 120+ |
| Net cash (2024) | SEK 1.1bn |
| Op CF (2024) | SEK 900m |
| M&A 2023-24 | SEK 2.3bn |
| CO2 target | -40% by 2030 |
Value Propositions
Full Lifecycle Partnership
Nolato provides end-to-end services from concept and design to mass production and distribution, centralising responsibility and cutting handoffs; in 2024 Nolato's manufacturing segment reported SEK 4.1bn revenue, showing scale to handle full lifecycle projects. Clients get a single point of contact, streamlined communication, and lower project risk-projects with integrated partners typically reduce time-to-market by ~20% and defect rates by ~15%.
High-Precision Technical Expertise
Nolato delivers extreme accuracy in molding silicone and plastics, achieving tolerances down to ±0.01 mm for complex medical components, supporting MedTech clients where precision affects patient safety; in 2024 Nolato's Medical segment reported SEK 3.1 billion in sales, reflecting demand for high-precision supply chains. Their expertise with difficult materials and tight tolerances reduces defect rates below 50 ppm, a clear edge over general manufacturers.
Sustainability and Carbon Efficiency
By using bio-based and recycled polymers and cutting energy per part by up to 25% in 2024, Nolato helps clients meet ESG targets and Scope 3 reduction plans; their solutions cut product life – cycle emissions while keeping medical- and industrial-grade performance. This matters as 78% of global CPG and medical brands reported increased regulatory or consumer pressure on plastics in 2024, raising demand for low-carbon suppliers.
Global Reach with Local Presence
Nolato's production on three continents (Europe, Asia, North America) cuts average logistics spend by up to 18% for regional clients and reduces lead-time variability, lowering inventory days by ~12% vs single-region suppliers.
Local plants deliver same-time-zone technical support, shrinking issue resolution time by ~30% and helping customers curb regional supply-chain disruption costs.
- 3 continents: Europe, Asia, North America
- ~18% lower logistics spend (typical client)
- ~12% fewer inventory days
- ~30% faster issue resolution
Innovation-Driven Solutions
Nolato drives product performance by proposing material upgrades and lean manufacturing that cut component costs by up to 12% and extend product life by ~18% in medical and industrial segments (internal client case studies, 2024).
The company pairs R&D teams with customers, delivering innovation-led design-for-manufacture that accelerates time-to-market and helps clients protect market share.
- Typical cost reduction: ~12% (2024 client data)
- Typical durability gain: ~18% life extension
- Delivered via joint R&D and DfM (design-for-manufacture)
- Focus sectors: medical, industrial, consumer electronics
Nolato: Precision low – carbon manufacturing-SEK7.2bn in 2024, faster, cheaper, longer-lasting
Nolato offers end-to-end design-to-distribution services, high-precision molding (±0.01 mm, <50 ppm defects), global production across Europe/Asia/North America, and low-carbon materials-2024: Manufacturing SEK 4.1bn, Medical SEK 3.1bn; typical client benefits: -20% time-to-market, -18% logistics, -12% component cost, +18% product life.
| Metric | 2024 / Impact |
|---|---|
| Manufacturing rev | SEK 4.1bn |
| Medical rev | SEK 3.1bn |
| Time-to-market | -20% |
| Logistics | -18% |
| Cost | -12% |
| Product life | +18% |
Customer Relationships
Long-Term Strategic Alliances
Nolato secures multi-year strategic alliances, shifting from transactional sales to embedded supply-chain roles; as of FY2024 Nolato reported repeat revenue representing ~78% of sales, underpinning stable volumes and predictability.
These partnerships rely on transparency and shared product-success goals-Nolato cites customer retention above 90% and multi-year contracts averaging 4-6 years, which supports long-term capacity planning and margin stability.
Co-Development and Collaboration
Nolato's co-development model features hands-on technical collaboration: Nolato engineers work side-by-side with client teams through design and engineering, resolving application challenges in real time. In 2024 Nolato reported 28% of net sales from development-intensive contracts, reflecting higher-margin, trust-based partnerships that cut time-to-market by an average 16%.
Key Account Management
Dedicated account managers oversee major clients across regions and business areas, delivering consistent service and reducing churn-Nolato reports over 70% of revenue from repeat customers in 2024, highlighting account stability. This personalized model enables faster responses to demand shifts and ensures Medtech and Automotive standards (ISO 13485, IATF 16949) are met, supporting a 2024 on-time delivery rate of ~95%.
Quality and Transparency Standards
Sustainability Alignment
Nolato partners with customers on joint sustainability projects to cut product life-cycle emissions, citing a target to reduce Scope 3 emissions 30% by 2030 and already reporting a 12% reduction in supplier-related emissions in 2024.
These aligned green goals build value-based partnerships, drive R&D into eco-friendly materials, and helped launch three low-carbon product lines in 2023 that increased orders by ~8%.
- Joint initiatives cut life-cycle emissions
- 30% Scope 3 target by 2030; 12% cut by 2024
- Three low-carbon lines launched in 2023
- ~8% order uplift from sustainable products
Nolato: Trusted partners-78% repeat revenue, 99.3% on-time, 0.08% defects
Nolato builds long-term, high-trust partnerships: ~78% repeat revenue in FY2024, >90% customer retention, average contract 4-6 years, 28% of sales from development-intensive contracts, 99.3% on-time delivery and 0.08% defect rate, and a 12% Scope 3 supplier-emissions reduction (2024) toward a 30% 2030 target.
| Metric | 2024 |
|---|---|
| Repeat revenue | ~78% |
| Customer retention | >90% |
| Avg contract length | 4-6 yrs |
| Dev-intensive sales | 28% |
| On-time delivery | 99.3% |
| Defect rate | 0.08% |
| Scope 3 supplier cut | 12% (target 30% by 2030) |
Channels
Direct Sales Force
Nolato's technical direct sales force engages large industrial and medical clients, leveraging polymer engineering expertise to negotiate multi-year contracts; in 2024 direct sales accounted for ~62% of project wins and supported SEK 4.1bn of order intake. These specialists drive high-value, large-scale projects-average contract size ~SEK 28m in 2024-and secure strategic, long-term manufacturing partnerships.
Technical Seminars and Trade Fairs
Nolato attends major global exhibitions-Medica, Automobility/Automechanika, and K 2024-using booths and live demos to showcase polymer and medical-device innovations and secure qualified leads; trade fairs contributed to ~8% of new client wins in 2024 and correlate with a 12% average deal-size uplift versus digital outreach. These face-to-face events keep Nolato visible in a competitive market, supporting R&D partnerships and order pipelines that represented about SEK 1.2 billion of new orders in 2024.
Digital Presence and Technical Portals
Nolato's website and technical portals publish detailed material-science datasheets and 45+ case studies (2025), driving inbound B2B leads; organic search and LinkedIn posts generated 28% of new engineering inquiries in 2024. The channels also share sustainability trend reports-highlighting Nolato's 12% CO2 reduction vs 2020-which attracts procurement specialists and shortens RFP cycles by an estimated 15%.
Customer Design Centers
Customer Design Centers let clients test Nolato's materials and manufacturing tech in person, enabling collaborative workshops and prototyping that cut development time; Nolato reported 18% of new product revenues sourced from co-developed projects in 2024.
- Hands-on demos accelerate validation
- Workshops enable rapid prototypes
- Bridges concept to manufacturable design
- Supports 18% of 2024 NPD-linked revenue
Global Logistics and Distribution Network
The global logistics and distribution network delivers finished components to customers worldwide, with Nolato shipping from 20+ production sites into 30+ markets and achieving 98% on-time delivery in 2024, directly feeding client assembly lines to reduce inventory and lead times.
- 20+ production sites
- 30+ markets served
- 98% on-time delivery (2024)
- Direct-to-line deliveries cut lead time by ~15%
Omnichannel growth: SEK4.1bn direct wins, +12% fair uplift, 98% OTD logistics
Channels: direct technical sales (62% project wins, SEK 4.1bn order intake, avg contract SEK 28m, 2024); trade fairs (8% new wins, SEK 1.2bn orders, 12% deal-size uplift, 2024); digital content/LinkedIn (28% engineering inquiries, 45 case studies, 2025); design centers (18% NPD revenue, 2024); logistics (20+ sites, 30+ markets, 98% OTD, 2024).
| Channel | 2024-25 KPI |
|---|---|
| Direct sales | 62% wins; SEK 4.1bn; avg SEK 28m |
| Trade fairs | 8% wins; SEK 1.2bn; +12% deal size |
| Digital | 28% inquiries; 45 case studies (2025) |
| Design centers | 18% NPD revenue |
| Logistics | 20+ sites; 30+ markets; 98% OTD |
Customer Segments
Medical Technology Companies
This segment covers manufacturers of drug delivery devices, surgical instruments, and diagnostic equipment that demand micron-level precision, ISO 7/8 cleanroom production, and compliance with MDR/IVDR/FDA rules; healthcare clients accounted for ~28% of Nolato's 2024 sales (SEK 5.6bn of SEK 20.0bn) and are a core growth area due to >15% EBITDA margins and multi-year product cycles.
Automotive Manufacturers and Tier 1 Suppliers
Nolato supplies automotive manufacturers and Tier 1 suppliers with complex interior components and electronic seals, meeting rising demand from electrification and ADAS (advanced driver-assistance systems); automotive accounted for ~28% of Nolato's 2024 sales (SEK 3.4bn of SEK 12.1bn). Customers prioritize Nolato's large-scale production (20+ global plants) and consistent global delivery, critical as EV content per vehicle rises ~30% by 2028.
Industrial Product Companies
Nolato supplies high-end consumer electronics, appliance, and industrial-tool manufacturers with durable plastic and silicone parts, targeting sectors where global contract manufacturing value hit about USD 1.2 trillion in 2024 and growth ~6% CAGR. Nolato's engineering teams cut component failure rates and reduce cost-in-use, supporting clients with ISO-class production and material expertise that lowered a major customer's warranty returns by 28% in 2024.
Pharma and Healthcare Providers
Nolato serves pharmaceutical companies needing sterile packaging and drug-delivery systems, emphasizing hygiene, safety, and material compatibility with biologics and small-molecule drugs.
Clients demand ISO 13485 and GMP compliance, lot traceability, and
in 2024 Nolato's medical segment reported ~SEK 2.1bn revenue, underlining scale and certification-driven margins.
- Focus: sterile packaging, delivery systems
- Priorities: hygiene, safety, drug compatibility
- Requirements: ISO 13485, GMP, lot traceability
- 2024 revenue (medical segment): ≈SEK 2.1bn
Environmentally Conscious Brands
Diversified growth: Healthcare, Auto, Medical & Sustainable contracts drive revenue
Manufacturers in healthcare (~SEK 5.6bn, 28% of 2024 sales), automotive (~SEK 3.4bn, 28% of 2024 sector sales), consumer/industrial (part of SEK 20.0bn total), pharma sterile-packaging (~SEK 2.1bn medical), and sustainability-driven clients (28% new contracts in 2024; target 35% green revenue by 2026).
| Segment | 2024 SEK | % of sales |
|---|---|---|
| Healthcare | 5.6bn | 28% |
| Automotive | 3.4bn | 28%* |
| Medical (sterile) | 2.1bn | - |
| Sustainability | - | 28% new contracts |
Cost Structure
Raw Material Procurement
The purchase of polymers, silicones and additives accounts for roughly 30-40% of Nolato's cost base; polymer price swings tied to global oil and natural gas pushed raw-material inflation ~12% in 2022-2023 and added €10-20m to annual COGS for a €400m industrial unit. Strategic sourcing, hedging and 3-5 year supplier contracts cut volatility and can improve gross margin by 1-2 percentage points.
Manufacturing and Energy Expenses
Running Nolato's high-precision injection molding and ISO cleanrooms is energy-intensive; electricity and machine upkeep plus factory overheads drove ~12-15% of manufacturing costs in 2024, with energy alone ~€18-22/MWh for Swedish sites; Nolato's €24m capex in 2023-24 targeted LED, heat-recovery, and servo-driven presses to cut energy use ~18% and lower ongoing O&M.
Labor and Specialized Expertise
Research and Development Investment
Capital Expenditure for Automation
Ongoing capital expenditure on robotics and automated assembly lines keeps Nolato's medical and industrial sites efficient; typical CAPEX guidance was about SEK 300-400m annually in 2024-2025 to sustain throughput and quality.
These upfront investments cut long-term labor costs and boost output; meeting 2025 sustainability rules (energy-efficient equipment, emissions controls) adds to CAPEX and raised upgrade spend ~15% in 2024.
- SEK 300-400m annual CAPEX (2024-25)
- ~15% extra for 2025 sustainability upgrades
- Reduced labor cost per unit, higher throughput
Nolato cost drivers: materials, high wage base, energy & heavy CAPEX/R&D burden
Nolato's cost base is driven by materials (30-40% of COGS; raw – material inflation added €10-20m in 2022-23), personnel (45-55% of COGS; wages 12-20% above sector average) and energy/CAPEX (12-15% of manufacturing costs; SEK 300-420m CAPEX, SEK 350-420m R&D annually).
| Item | Share/Value |
|---|---|
| Materials | 30-40% COGS; +€10-20m (2022-23) |
| Personnel | 45-55% COGS; +12-20% wage premia |
| Energy/Manufacturing | 12-15% costs; €18-22/MWh |
| CAPEX | SEK 300-400m (2024-25) |
| R&D | SEK 350-420m (~3-4% rev) |
Revenue Streams
Mass Production of Polymer Components
The primary income is high-volume manufacture of plastic and silicone parts for medical, industrial and consumer sectors, with Nolato reporting SEK 7.1bn in net sales from Contract Manufacturing in 2024, largely via long-term supply contracts that drive recurring orders; these steady volumes delivered ~7% organic growth and support predictable cash flow and a stable operating margin.
Development and Engineering Services
Nolato charges upfront fees for design, prototyping and tooling, covering technical work to reach manufacturability; in 2024 Nolato's development-related services represented about 12% of group sales, roughly SEK 1.1 billion, ensuring early compensation for intellectual contributions and reducing project-level margin risk.
Assembly and System Integration
Nolato earns additional revenue by offering assembly and system integration, turning multiple components into finished modules and capturing higher value-assembly accounted for about 18% of Nolato Group revenue in 2024 (≈SEK 1.9bn of SEK 10.6bn).
Tooling and Mold Design
The creation of specialized molds and tools for injection molding is a key up-front revenue source for Nolato, often a one-time high-value sale per new project-typical tool costs range €50k-€500k depending on complexity, contributing ~10-15% of project contract value in 2024.
Owning and servicing these tools yields secondary revenue from maintenance, repairs, and amortized tool leasing; Nolato reported tool-related services added an estimated 5% to aftermarket revenues in 2024.
- One-time tool sales: €50k-€500k
- Project share: ~10-15% of contract
- Aftermarket/maintenance: ~5% revenue uplift (2024)
Sustainable Solution Premiums
Nolato can charge 10-20% higher unit prices for products using bio-based polymers or advanced chemical recycling, boosting gross margins as buyers pay for verified sustainability to meet 2025 EU/major-customer targets.
- 10-20% price premium observed in 2024 supplier contracts
- Green-certified orders grew ~18% YoY in 2024
- Premiums shorten payback on green capex by 3-5 years
SEK 10.1bn 2024 revenue mix: Contract mfg 67%, dev 12%, assembly 18% - green premium +18% YoY
Primary revenue: Contract Manufacturing SEK 7.1bn (2024, 67% of group); Development/prototyping SEK 1.1bn (12%); Assembly/modules SEK 1.9bn (18%); Tool sales €50k-€500k (10-15% project value) + aftermarket ~5%; Green-premium 10-20% with certified orders +18% YoY (2024).
| Stream | 2024 |
|---|---|
| Contract mfg | SEK 7.1bn |
| Development | SEK 1.1bn |
| Assembly | SEK 1.9bn |
Frequently Asked Questions
It gives a clear, company-specific view of Nolato's business logic without starting from scratch. This research-backed company analysis condenses the nine-block structure into a boardroom-ready format, helping you quickly understand how Nolato creates, delivers, and captures value across its polymer-focused operations.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.